Innovative Therapeutics in Oncology and Neuroscience

28 Tumor Treating Fields Late-stage Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint Primary Data Summary of LUNAR study (N=276) LUNAR Phase 3 Trial of TTFields with Standard of Care for Metastatic Non-Small Cell Lung Cancer Key Secondary • OS with TTFields + SOC OS in ICI-treated subgroup vs SOC alone • OS in docetaxel-treated subgroup TTFields + SOC provided a statistically significant and clinically meaningful 3-month improvement in mOS vs SOC ➤ Statistically significant ~8-month increase in mOS with TTFields an ICI (from 10.8 to 18.5 months) There was a 2.4-month difference in mOS with TTFields + docetaxel (from 8.7 to 11.1 months) No added systemic toxicities Next Steps and Core Opportunity Next Steps • Core Opportunity Lung cancer is the most common cancer type • FDA accepted for filing the Premarket Approval (PMA) application in January 2024 for treatment of 2L+ NSCLC in China, with ~740K new NSCLC cases¹ diagnosed each year . Zai Lab plans to submit Marketing Authorization Application (MAA) to the NMPA for this indication in 2024, following the U.S. submission • Initiative on reimbursement for innovative medical devices - first access planned at provincial level2 Note: (1) Changfa Xia, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants; (2) In May 2023, NHSA published an announcement collecting opinions on making related polices regarding the medical insurance listing for consumables at the provincial level. Clinical Data - Oncology

View entire presentation